On September 22, 2022 Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, reported that Founder and Chief Medical Officer Prof David Kerr had been made a Fellow of the European Society for Medical Oncology (Press release, Celleron, SEP 22, 2022, View Source [SID1234621332]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) is committed to offering the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.
In 2022 the Society introduced a Fellow of ESMO (Free ESMO Whitepaper) (FESMO) Award Programme, to recognise, thank, and reward ESMO (Free ESMO Whitepaper) Members who have demonstrated exceptional commitment to the Society. Prof David Kerr, Oxford, UK was selected as one of the first recipients of this honour, bestowed at the Paris ESMO (Free ESMO Whitepaper) Congress.
Professor Kerr CBE MD DSc FRCP FRGCP FACP FESMO FMedSci is a British medical oncologist with over 40 years experience in cancer research. His primary interest is the treatment and management of bowel cancer. He is currently Professor of Cancer Medicine at the University of Oxford, and holds the additional positions of Honorary Consultant Medical Oncologist, Oxford Cancer Centre; Co-Director, Oxford-Sichuan Gastrointestinal Cancer Centre; Honorary Professor of Oncology, Sichuan, Suchow, Xiamen, Zhejiang and 2nd Military Universities, China; and Honorary Professor, Seoul National University, Korea.
In the commercial sector, he has co-founded companies such as Cobra Therapeutics, Oxford Cancer Biomarkers, Celleron Therapeutics, and SynOx Therapeutics.
Professor Kerr was President of ESMO (Free ESMO Whitepaper) from 2010-2012.
Professor David Kerr, Chief Medical Officer and Founder of Celleron Therapeutics, and Professor of Cancer Medicine at Oxford University, commented:
"I am proud to have made some small contribution towards ESMO (Free ESMO Whitepaper)’s progress to become one of the world’s leading professional societies, embracing cancer physicians from almost every nation on the globe. ESMO (Free ESMO Whitepaper)’s guiding philosophy, Good science, Better medicine, Best practice is equally well as applicable to Celleron’s approach to developing novel cancer therapeutics ".